Use of helium-neon laser in patients with melasma
Keywords:
melanosis, helium-neon laser, hydroquinone.Abstract
Introduction: Melasma is a hyperpigmentation of the skin located in photo-exposed areas, which is caused by an increase in epidermal or dermal melanin, or both, which sometimes affects the self-esteem of men and women.
Objective: To assess the effectiveness of helium-neon laser treatment in patients with melasma.
Methods: A quasi-experimental study of therapeutic intervention was carried out in 34 patients with a clinical and dermoscopic diagnosis of melasma, treated at the dermatology clinic of the Dr. Juan Bruno Zayas General Teaching Hospital in Santiago de Cuba, from January 2019 to the same month of January 2019. 2020, for which two groups were formed: I (or intervention), which received laser treatment, and II (control), treated with 2% hydroquinone cream. The information was processed and expressed in absolute values and percentage; likewise, if necessary, the Χ2 parametric homogeneity test was used to search for association between the groups, with a significance level of α=0.05.
Results: Most of the patients were between the ages of 39-48 years old, female, with mixed skin color and medium-sized lesions with evaluations at the beginning, at the end of treatment, one month and 3 months after finishing it.
Results: The use of helium-neon laser was effective in the patients, with no statistically significant differences in terms of therapeutic response between both groups and no adverse events.
Downloads
References
2. Rajanala S, Catro Maymone MB, Vashi NA. Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies. Dermatol Online J. 2019 [citado 22/10/2022];25(10). Disponible en: file:///C:/Users/aula1/Downloads/eScholarship%20UC%20item%2047b7r28c.pdf
3. Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res. 2018 [citado 22/10/2022];31(4):461-5. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/pcmr.12684
4. McKesey J, Tovar Garza A, Pandya AG. Melasma treatment: an Evidence-Based Review. Am J Clin Dermatol. 2020;21(2):173-225.
5. Fioranelli M, Jafferany M, Wollina U, Tirant M, Thuong NV, Lotti T. New local treatments for different types of melasma: vascular type vs. nonvascular type. A randomized polycentric study. Dermatol Ther. 2020;33(3):e13300.
6. Kwon SH, Na JI, Choi JY, Park KC. Melasma: updates and perspectives. Exp Dermatol. 2019 [citado 22/10/2022];28(6):704-8. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/exd.13844
7. Zhou LL, Baibergenova A. Melasma: systematic review of the systemic treatments. Int J Dermatol. 2017 [citado 22/10/2022];56(9):902-8. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/ijd.13578
8. Deshpande SS, Khatu SS, Pardeshi GS, Gokhale NR. Cross-sectional study of psychiatric morbidity in patients with melasma. Indian J Psychiatry. 2018 [citado 22/10/2022];60(3):324–8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201670/
9. Crespo JC, Zaragoza Rubira. El láser MID en Dermatología. Sevilla: Universidad de Sevilla; 2001. p. 190-201.
10. López Valdés EA. Calidad de vida en las pacientes con Melasma. San Juan Ostuncalco, Quetzaltenango, Guatemala [tesis]. Nueva Guatemala de la Asunción: Universidad Rafael Saldívar; 2017 [citado 22/10/2022]. Disponible en: http://recursosbiblio.url.edu.gt/tesisjrcd/2017/09/18/L%C3%B3pez-Elmer.pdf
11. Rao KrupaShankar DS, Somani VK, Kohli M, Sharad J, Ganjoo A, Kandhari S, et al. A cross sectional, multicentric clinic-epidemiological study of melasma in India. Dermatol Ther (Heidelb). 2014 [citado 22/10/2022];4(1):71–81. Disponible en: https://link.springer.com/article/10.1007/s13555-014-0046-1
12. Kumar S, Mahajan BB, Kamra N. Melasma in North Indians: A clinical, epidemiological, and etiological study. Pigment International. 2014 [citado 22/10/2022];1(2):95-9. Disponible en: https://www.pigmentinternational.com/article.asp?issn=2349-5847;year=2014;volume=1;issue=2;spage=95;epage=99;aulast=Kumar
13. Kaur J, Kaur T. A prospective, randomised, split-face comparative study of 50% glycolic acid peel versus laser toning in the treatment of melasma in Asian skin. Int J Res Dermatol. 2020 [citado 22/10/2022];6(3):371-5. Disponible en: file:///C:/Users/aula1/Downloads/medip,+IJORD-954+O.pdf
14. Jin Y, Jiang W, Yao Y, Huang H, Huang J. Clinical efficacy of laser combined with menstrual regulation in the treatment of female melasma: a retrospective study. Lasers Med Sci. 2019;34(6):1099-105.
15. Dagdug Villegas AG, Guevara Hernández C, Arellano Mendoza I. Actualidades en el tratamiento de melasma. Dermatología CMQ. 2020 [citado 22/10/2022];18(4):307-17. Disponible en: https://www.medigraphic.com/pdfs/cosmetica/dcm-2020/dcm204m.pdf
16. Arellano Mendoza I. Guías de diagnóstico y manejo del melasma. Dermatología CMQ. 2018 [citado 22/10/2022];16(1). Disponible en: https://www.medigraphic.com/pdfs/cosmetica/dcm-2018/dcm181c.pdf
17. Vanaman Wilson MJ, Jones IT, Bolton J, Larsen L, Guillen Fabi S. The Safety and Efficacy of Treatment with a 1,927-nm Diode Laser with and without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types. Dermatol Surg. 2018;44(10):1304-10.
18. Hofbauer Parra CA, Figueroa Careta M, Sakai Valente NY, Guimaraes de Sanches Osorio NE, Ribeiro Torezan LA. Clinical and histopathologic assessment of facial melasma after low-fluence Q-switched neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2016;42(4):507-12.
19. Taghavi F, Banihashemi M, Zabolinejad N, Salehi M, Jaafari MR, Marhamati H et al. Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma. J Cosmet Dermatol. 2019;18(3):870-3.
Published
How to Cite
Issue
Section
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.